To provide further insights into your compound's mechanism of action, we offer a panel of tests, including immunohistochemistry, flow cytometry, molecular biology methods and determination of enzyme activity.
Inhibition of cell signalling by your compound can be measured by bead suspension arrays or multichannel FACS. Using suspension arrays, up to ten different signalling molecules can be measured simultaneously.
Flow cytometry can be used to assess the ability of your compound to induce immunostimulating cytokines after treatment with peripheral blood mononuclear cells (PBMC) or any other stimulation.
Induction of apoptosis by your compound is measured in cell lines of interest by active caspase 3 in a 96-well format or by FACS analysis using parameters such as Annexin V.
We can test your compound's capacity to inhibit cell migration using assays that are designed for a 96-well format. We also offer purification of blood cells to perform migration assays on primary cells.
We can test the effect of your compound on the growth of a wide range of cancer cell lines using high throughput assays.
We can test your compound's anti-angiogenesis potential using AngioChamber(tm)assays. This type of assay allows us to fill the chamber with chosen growth factors captured in agarose, which induce a wound healing process and the development of a fibrous capsule. The capsule is highly vascularised when loaded with growth factors. The wet weight of the capsule correlates with the induction of blood vessel development and is used to quantify the inhibition of blood vessel development. We can also use human umbilical vein endothelial (HUVE) cells, plated in 96-well microtitre plates on Matrigel, to quantify capillary formation.
We can perform in vitro pharmacokinetic models, which are excellent tools with which to study your compound's pharmacodynamics (PD). They can be used to perform simple descriptive studies on your compound's effect and determine the dominant PD factor and its magnitude for efficacy.